Birth Control Center

Birth Control Care Center abortion clinic in Las Vegas, Nevada.

Alternatives Salon

Alternatives Salon is a leader among hair salons in Stroudsburg, PA, highly recognized for providing the best in natural hair care and expert makeup services.

Circadian Technologies Limited

Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company focused on the development of biologics-based therapies for the treatment of cancer and eye disease. Circadian owns an extensive patent portfolio covering targets (VEGF-C, VEGF-D, VEGFR-3) and drugs (VGX-100 and VGX-300) to modulate the processes of angiogenesis - the development of blood vessels within the body and lymphagiogenesis-the development of lymphatics in the human body. Circadian's product pipeline includes biologics drugs targeting important mediators of angiogenesis and lymphangiogenesis. Circadian's lead development candidate, VGX-100, is a fully human antibody that inhibits the VEGF-C protein. VGX-100 is currently in Phase 1a and Phase 1b clinical trials in late stage cancer patients at 2 leading US cancer centres. These studies are being done under an IND. Phase 2 studies are expected to commence in H2 2013. VGX-100 and VGX-300 are also being developed as agents to treat age related macular degeneration in patients non-responsive to anti-VEGF-A therapy. VEGF-C and VEGFR-3 have been shown to play a major role in retinal angiogenesis. VGX-100 and VGX-300 have been shown to be effective in animal models of back of the eye disease. They are currently in pre-clinical development with clinical development expected to commence by H1 2014.

Faséo

Faséo est bureau d'études créé par Benoît Géhin le 25 mars 2005 qui se base sur l'expérience de son dirigeant, lequel avait alors plus de quinze années d'expérience sur les chantiers et au sein de bureaux d'études. Faséo s'appuie aussi sur les énergies complémentaires d'une équipe d'ingénieurs, de techniciens, de projeteurs et de dessinateurs chacun experts dans leurs spécialités respectives. Depuis bientôt 12 ans, Faséo a su gagner la confiance de ses clients concernant l'ingénierie de leurs projets. Que ce soient de la maitrise d'œuvre, de l'assistance techniques, des études de faisabilité, des créations de cahier des charges, des dossiers de consultation, des évaluations de budget, des analyses techniques et financières des offres ou l'exécution des différents plans ou schémas, Faséo a su accompagner ceux qui lui ont fait confiance. Mais Faséo est surtout une entreprise dynamique qui cherche sans cesse à adapter son savoir-faire à l'évolution rapide de l'univers du bâtiment. Initialement bureau d'études en électricité, nous avons rapidement su évoluer avec les progrès actuels en travaillant par exemple sur des projets tous fluides, en apprenant à maîtriser la gestion technique (domotique, GTB et GTC) et les énergies renouvelables. Soucieux de la trace que nous laisserons, nous cherchons toujours à favoriser des solutions respectueuses de l'environnement.

DeNova Research

DeNova Research is a clinical research center specializing in the fields of aesthetic medicine, plastic surgery and dermatology. With over 80 years of combined research experience, our qualified team of physicians, research coordinators and physician assistants has cemented itself as a company committed to strong ethical standards and dedicated to produce clean, accurate data. DeNova Research understands the timely nature of new product development and clinical research. Our reputation for a quick and efficient turnaround for new protocol proposals, regulatory submissions and budget and contract negotiations allows for a swift transition towards execution of your project. From new protocol development to clinical trial execution, DeNova Research delivers quality, ethical research. With an on-site clinical practice seeing more than 6,500 patient visits yearly, a unique research patient/photo database of more than 7,500 subjects and a dedicated recruitment and retention specialist, DeNova Research excels at an expeditious enrollment process reaching 119% of our enrollment goals with a retention rate of 94% in the last 3 years.